可选产品分析
经您允许,我们会使用注重隐私的有限分析来了解哪些研究流程有效。我们不会使用广告跟踪器或会话录制。您可以在偏好设置中更改此选择。请阅读 隐私政策.
Kenvue Inc.'s published Hold conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $33.0B | |
|---|---|---|
| Revenue (ttm) | 15.4B | |
| Net income (ttm) | 1.7B | |
| EPS (ttm) | $0.85 | |
| Shares out | 1.9B | |
| P/E (trailing) | 22.7x | |
| P/E (forward) | 14.7x | |
| Dividend | $0.84 (4.34%) | |
| Volume | 6,839,244 | |
| Beta | 0.45 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2022-01-02 | 2023-01-01 | 2023-12-31 | 2024-12-29 | 2025-12-28 | Trend |
| Revenue | $15.05B | $14.95B | $15.44B | $15.46B | $15.12B | +0.1% |
| Gross profit | $8.42B | $8.29B | $8.64B | $8.96B | $8.79B | +1.1% |
| Operating income | $2.92B | $2.68B | $2.51B | $1.84B | $2.41B | -4.6% |
| Net income | $2.08B | $2.06B | $1.66B | $1.03B | $1.47B | -8.3% |
| EPS (diluted) | $1.21 | $1.20 | $0.90 | $0.54 | $0.76 | -11.0% |
| EBITDA | $3.66B | $3.28B | $3.18B | $2.47B | $2.94B | -5.3% |
| R&D | $355.0M | $375.0M | $399.0M | $408.0M | $382.0M | +1.8% |
| SG&A | $5.48B | $5.63B | $6.14B | $6.33B | $6.09B | +2.6% |
Recent company headlines from major financial publishers.
The base outcome assumes steady consumer replenishment in non-discretionary over-the-counter healthcare categories, maintaining predictable top-line progression and stable operating margins. Steady channel execution preserves shelf placement across mass retail partners while cash generation covers regular dividends and scheduled debt maturities. This modal path projects a target of $18.17 with an estimated probability of 55.0%, delivering an implied return of 5.6% against $17.20 (as of 2026-10-02).
In the bull outcome, brand reinvestment and strong clinical positioning accelerate organic revenue expansion across Self Care and international territories. Operating efficiencies expand operating margins toward peer benchmark levels, unlocking superior cash generation. At a target value of $23.53 carrying an estimated probability of 20.0%, this path offers an implied return of 36.8% relative to $17.20 (as of 2026-10-02).
| Ke ↓ / g → | 1.5% | 1.8% | 2.0% | 2.3% | 2.5% |
|---|---|---|---|---|---|
| 6.2% | $20.0 | $20.7 | $21.4 | $22.2 | $23.1 |
| 6.7% | $18.5 | $19.0 | $19.6 | $20.3 | $21.0 |
| 7.2% | $17.3 | $17.7 | $18.2 | $18.7 | $19.3 |
| 7.7% | $16.2 | $16.6 | $16.9 | $17.4 | $17.8 |
| 8.2% | $15.3 | $15.6 | $15.9 | $16.2 | $16.6 |
Upcoming earnings date and setup when available.
每月发布的研究版本所给出的评级。评级比较分析日的价格与公允价值,并不记录判断是否正确。
| 年份 | 1月 | 2月 | 3月 | 4月 | 5月 | 6月 | 7月 | 8月 | 9月 | 10月 | 11月 | 12月 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |